Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04964934
Registration number
NCT04964934
Ethics application status
Date submitted
30/06/2021
Date registered
16/07/2021
Titles & IDs
Public title
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
Query!
Scientific title
A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study
Query!
Secondary ID [1]
0
0
2023-503990-39-00
Query!
Secondary ID [2]
0
0
D8534C00001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SERENA-6
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
ER-Positive HER2-Negative Breast Cancer
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - AZD9833
Treatment: Drugs - AZD9833 Placebo
Treatment: Drugs - Anastrozole
Treatment: Drugs - Anastrozole placebo
Treatment: Drugs - Letrozole
Treatment: Drugs - Letrozole placebo
Treatment: Drugs - Palbociclib
Treatment: Drugs - Abemaciclib
Treatment: Drugs - Luteinizing hormone-releasing hormone (LHRH) agonist
Treatment: Drugs - Ribociclib
Experimental: AZD9833 + palbociclib, abemaciclib or ribociclib - The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150,100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + anastrozole placebo (PO, once daily) or letrozole placebo (PO, once daily)
Active comparator: Anastrozole or letrozole + palbociclib, abemaciclib or ribociclib - The patients will recieve anastrozole (1 mg, PO, once daily) or letrozole (2.5 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150, 100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + AZD9833 placebo (PO, once daily)
Treatment: Drugs: AZD9833
Dosage formulation: AZD9833 tablets will be administered orally
Treatment: Drugs: AZD9833 Placebo
Dosage formulation: AZD9833 placebo tablets will be administrated orally.
Treatment: Drugs: Anastrozole
Dosage formulation: anastrozole tablets will be administered orally.
Treatment: Drugs: Anastrozole placebo
Dosage formulation: anastrozole placebo tablets will be administrated orally.
Treatment: Drugs: Letrozole
Dosage formulation: letrozole tablets will be administered orally.
Treatment: Drugs: Letrozole placebo
Dosage formulation: letrozole placebo tablets will be administered orally.
Treatment: Drugs: Palbociclib
Dosage formulation: palbociclib tablets/capsules will be administered orally
Treatment: Drugs: Abemaciclib
Dosage formulation: abemaciclib tablets will be administered orally
Treatment: Drugs: Luteinizing hormone-releasing hormone (LHRH) agonist
Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
Treatment: Drugs: Ribociclib
Dosage formulation: ribociclib tablets will be administered orally
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1)
Query!
Assessment method [1]
0
0
PFS is defined as the time from randomization to objective disease progression (as assessed by RECIST 1.1) or death.
Query!
Timepoint [1]
0
0
From randomization until the earlier of the progression event or death (approximately 2 years)
Query!
Secondary outcome [1]
0
0
Progression-free survival 2 (PFS2)
Query!
Assessment method [1]
0
0
PFS2 is defined as the time from the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death.
Query!
Timepoint [1]
0
0
From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (approximately 3.5 years)
Query!
Secondary outcome [2]
0
0
Overall survival (OS)
Query!
Assessment method [2]
0
0
The OS is defined as the time from randomization to death due to any cause.
Query!
Timepoint [2]
0
0
From randomization until the date of death due to any cause (approximately 5 years)
Query!
Secondary outcome [3]
0
0
Chemotherapy free survival
Query!
Assessment method [3]
0
0
Time to chemotherapy is defined as the time from randomization until the earlier of the start date of chemotherapy or death due to any cause.
Query!
Timepoint [3]
0
0
From randomization until the earlier of the start date of chemotherapy or death due to any cause (approximately 5 years)
Query!
Secondary outcome [4]
0
0
Objective response rate (ORR) assessed by the Investigator as defined by RECIST version 1.1
Query!
Assessment method [4]
0
0
ORR is defined as the proportion of patients who have a complete response (CR) or partial response (PR), as determined by the investigator at local site per RECIST 1.1.
Query!
Timepoint [4]
0
0
From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 5 years)
Query!
Secondary outcome [5]
0
0
Clinical benefit rate at 24 weeks (CBR24)
Query!
Assessment method [5]
0
0
CBR at 24 weeks is defined as the percentage of participants who have a complete response (CR) or partial response or who have stable disease (SD) per RECIST 1.1 as assessed by the investigator at local site for At least 23 weeks after randomisation for each patient to allow for an early assessment within the assessment window (1 week window for RECIST assessment)
Query!
Timepoint [5]
0
0
At least 23 weeks after randomisation for each patient (1 week window for RECIST assessment)
Query!
Secondary outcome [6]
0
0
Change from baseline in EORTC QLQ-C30 scale scores
Query!
Assessment method [6]
0
0
Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Scale scores range from 0-100. For functioning and global health status/ QoL scales, higher scores indicate better functioning or global health status/QoL. For symptom scales, higher scores indicate greater symptom burden.
Query!
Timepoint [6]
0
0
From baseline until second progression (approximately 5 years)
Query!
Secondary outcome [7]
0
0
Change from baseline in EORTC QLQ-BR23 scale scores
Query!
Assessment method [7]
0
0
Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module (EORTC QLQ-BR23). Scale scores range from 0-100. For functioning scales, higher scores indicate better functioning. For symptom scales, higher scores indicate greater symptom burden.
Query!
Timepoint [7]
0
0
From baseline until second progression (approximately 5 years)
Query!
Secondary outcome [8]
0
0
Plasma concentration of AZD9833 at specified timepoints
Query!
Assessment method [8]
0
0
To assess the steady state PK of AZD9833 in combination with palbociclib or abemaciclib in all participants who receive at least one dose of AZD9833 per the protocol, for whom there are at least one reportable PK concentration.
Query!
Timepoint [8]
0
0
on Day 15 for each patient
Query!
Eligibility
Key inclusion criteria
INCLUSION CRITERIA:
INFORMATION FOR TRIAL PARTICIPANTS - Participants can join the trial if they:
* Have advanced breast cancer that is not able to be treated with surgery or radiation;
* Have an ESR1 mutation in their cancer;
* Have breast cancer that is HR-positive and HER2-negative;
* Are currently being treated with a CDK4/6 inhibitor and an AI and have been taking these drugs for at least 6 months;
* Have not had their cancer get worse after taking an AI and CDK4/6 inhibitor;
* Are able to do their daily activities;
* Are at least 18.
Full list of inclusion criteria:
* Proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent;
* Documentation of histologically confirmed diagnosis of estrogen receptor positive (ER+) /HER2- breast cancer based on local laboratory results;
* Currently on AI (letrozole or anastrozole) + CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) ± LHRH as the initial endocrine based treatment for advanced disease;
* Eastern Cooperative Oncology Group performance status of 0 or 1;
* ESR1m detected by central testing of ctDNA;
* Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;
* Adequate organ and marrow function.
EXCLUSION CRITERIA:
INFORMATION FOR TRIAL PARTICIPANTS - Participants cannot join the trial if they:
* Had certain types of tumors in the past that may come back;
* Are currently taking any other treatments for their cancer or other conditions including hormone replacements, medications, or supplements that could interfere with the trial treatment;
* Have or have had any major health problem, infection, or recent surgery that could make it difficult or dangerous to participate in this trial.
Full list of exclusion criteria:
* Advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term;
* Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease;
* Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol;
* Patient with known or family history of severe heart disease;
* Previous treatment with AZD9833, investigational SERDs or fulvestrant;
* Currently pregnant (confirmed with positive pregnancy test) or breastfeeding;
* Persistent non-haematological toxicities (CTCAE Grade > 2) caused by CDK4/6 inhibitor and/or AI treatment.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
130
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
30/06/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
26/11/2027
Query!
Actual
Query!
Sample size
Target
300
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Birtinya
Query!
Recruitment hospital [2]
0
0
Research Site - Darlinghurst
Query!
Recruitment hospital [3]
0
0
Research Site - Subiaco
Query!
Recruitment postcode(s) [1]
0
0
4575 - Birtinya
Query!
Recruitment postcode(s) [2]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [3]
0
0
6008 - Subiaco
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Massachusetts
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Minnesota
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Mississippi
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Missouri
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Montana
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Nebraska
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New Jersey
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New York
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
North Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Ohio
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Oregon
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Pennsylvania
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
South Carolina
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Tennessee
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Texas
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Utah
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Virginia
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Washington
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Wisconsin
Query!
Country [30]
0
0
Austria
Query!
State/province [30]
0
0
Graz
Query!
Country [31]
0
0
Austria
Query!
State/province [31]
0
0
Innsbruck
Query!
Country [32]
0
0
Austria
Query!
State/province [32]
0
0
Salzburg
Query!
Country [33]
0
0
Austria
Query!
State/province [33]
0
0
Wien
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Leuven
Query!
Country [35]
0
0
Belgium
Query!
State/province [35]
0
0
Liège
Query!
Country [36]
0
0
Belgium
Query!
State/province [36]
0
0
Namur
Query!
Country [37]
0
0
Bulgaria
Query!
State/province [37]
0
0
Haskovo
Query!
Country [38]
0
0
Bulgaria
Query!
State/province [38]
0
0
Panagyurishte
Query!
Country [39]
0
0
Bulgaria
Query!
State/province [39]
0
0
Pleven
Query!
Country [40]
0
0
Bulgaria
Query!
State/province [40]
0
0
Plovdiv
Query!
Country [41]
0
0
Bulgaria
Query!
State/province [41]
0
0
Sofia
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Alberta
Query!
Country [43]
0
0
Canada
Query!
State/province [43]
0
0
British Columbia
Query!
Country [44]
0
0
Canada
Query!
State/province [44]
0
0
Quebec
Query!
Country [45]
0
0
Canada
Query!
State/province [45]
0
0
Ottawa
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Avignon Cedex 09
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Brest
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Clermont-Ferrand
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Dijon
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Limoges
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Lorient cedex
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Lyon Cedex 08
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Marseille
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Metz-Tessy
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Nimes
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Paris Cedex 5
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Rouen
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Saint Herblain Cedex
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Saint-cloud
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Toulouse
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Tours
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Vandoeuvre les Nancy
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Vantoux
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Villejuif Cedex
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Ansbach
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Aschaffenburg
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Augsburg
Query!
Country [68]
0
0
Germany
Query!
State/province [68]
0
0
Bonn
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Chemnitz
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Dresden
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Erlangen
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Essen
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Freiburg
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Immenstadt
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Koblenz
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Leipzig
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Mannheim
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
München
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Paderborn
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Ratingen
Query!
Country [81]
0
0
Germany
Query!
State/province [81]
0
0
Ravensburg
Query!
Country [82]
0
0
Germany
Query!
State/province [82]
0
0
Regensburg
Query!
Country [83]
0
0
Germany
Query!
State/province [83]
0
0
Stade
Query!
Country [84]
0
0
Germany
Query!
State/province [84]
0
0
Tübingen
Query!
Country [85]
0
0
Germany
Query!
State/province [85]
0
0
Ulm
Query!
Country [86]
0
0
Hungary
Query!
State/province [86]
0
0
Budapest
Query!
Country [87]
0
0
Hungary
Query!
State/province [87]
0
0
Miskolc
Query!
Country [88]
0
0
Hungary
Query!
State/province [88]
0
0
Szekszárd
Query!
Country [89]
0
0
Hungary
Query!
State/province [89]
0
0
Szolnok
Query!
Country [90]
0
0
Hungary
Query!
State/province [90]
0
0
Zalaegerszeg
Query!
Country [91]
0
0
Israel
Query!
State/province [91]
0
0
Beer Sheva
Query!
Country [92]
0
0
Israel
Query!
State/province [92]
0
0
Haifa
Query!
Country [93]
0
0
Israel
Query!
State/province [93]
0
0
Jerusalem
Query!
Country [94]
0
0
Israel
Query!
State/province [94]
0
0
Petah Tikva
Query!
Country [95]
0
0
Israel
Query!
State/province [95]
0
0
Ramat Gan
Query!
Country [96]
0
0
Italy
Query!
State/province [96]
0
0
Bergamo
Query!
Country [97]
0
0
Italy
Query!
State/province [97]
0
0
Bologna
Query!
Country [98]
0
0
Italy
Query!
State/province [98]
0
0
Firenze
Query!
Country [99]
0
0
Italy
Query!
State/province [99]
0
0
Meldola
Query!
Country [100]
0
0
Italy
Query!
State/province [100]
0
0
Milano
Query!
Country [101]
0
0
Italy
Query!
State/province [101]
0
0
Milan
Query!
Country [102]
0
0
Italy
Query!
State/province [102]
0
0
Misterbianco
Query!
Country [103]
0
0
Italy
Query!
State/province [103]
0
0
Napoli
Query!
Country [104]
0
0
Italy
Query!
State/province [104]
0
0
Padova
Query!
Country [105]
0
0
Italy
Query!
State/province [105]
0
0
Roma
Query!
Country [106]
0
0
Italy
Query!
State/province [106]
0
0
Rozzano
Query!
Country [107]
0
0
Japan
Query!
State/province [107]
0
0
Chiba-shi
Query!
Country [108]
0
0
Japan
Query!
State/province [108]
0
0
Chuo-ku
Query!
Country [109]
0
0
Japan
Query!
State/province [109]
0
0
Hidaka-shi
Query!
Country [110]
0
0
Japan
Query!
State/province [110]
0
0
Hirakata-shi
Query!
Country [111]
0
0
Japan
Query!
State/province [111]
0
0
Kitaadachi-gun
Query!
Country [112]
0
0
Japan
Query!
State/province [112]
0
0
Koto-ku
Query!
Country [113]
0
0
Japan
Query!
State/province [113]
0
0
Kumamoto-shi
Query!
Country [114]
0
0
Japan
Query!
State/province [114]
0
0
Matsuyama-shi
Query!
Country [115]
0
0
Japan
Query!
State/province [115]
0
0
Nagoya-shi
Query!
Country [116]
0
0
Japan
Query!
State/province [116]
0
0
Niigata-shi
Query!
Country [117]
0
0
Japan
Query!
State/province [117]
0
0
Osaka-shi
Query!
Country [118]
0
0
Japan
Query!
State/province [118]
0
0
Ota-shi
Query!
Country [119]
0
0
Japan
Query!
State/province [119]
0
0
Sapporo-shi
Query!
Country [120]
0
0
Japan
Query!
State/province [120]
0
0
Shinagawa-ku
Query!
Country [121]
0
0
Japan
Query!
State/province [121]
0
0
Shinjuku-ku
Query!
Country [122]
0
0
Japan
Query!
State/province [122]
0
0
Takasaki-shi
Query!
Country [123]
0
0
Japan
Query!
State/province [123]
0
0
Takatsuki-shi
Query!
Country [124]
0
0
Japan
Query!
State/province [124]
0
0
Tsukuba
Query!
Country [125]
0
0
Japan
Query!
State/province [125]
0
0
Yokohama-shi
Query!
Country [126]
0
0
Korea, Republic of
Query!
State/province [126]
0
0
Cheonan-si
Query!
Country [127]
0
0
Korea, Republic of
Query!
State/province [127]
0
0
Daegu
Query!
Country [128]
0
0
Korea, Republic of
Query!
State/province [128]
0
0
Goyang-si
Query!
Country [129]
0
0
Korea, Republic of
Query!
State/province [129]
0
0
Seongnam-si
Query!
Country [130]
0
0
Korea, Republic of
Query!
State/province [130]
0
0
Seongnam-Si
Query!
Country [131]
0
0
Korea, Republic of
Query!
State/province [131]
0
0
Seoul
Query!
Country [132]
0
0
Norway
Query!
State/province [132]
0
0
Drammen
Query!
Country [133]
0
0
Norway
Query!
State/province [133]
0
0
Oslo
Query!
Country [134]
0
0
Poland
Query!
State/province [134]
0
0
Bydgoszcz
Query!
Country [135]
0
0
Poland
Query!
State/province [135]
0
0
Gdynia
Query!
Country [136]
0
0
Poland
Query!
State/province [136]
0
0
Konin
Query!
Country [137]
0
0
Poland
Query!
State/province [137]
0
0
Koszalin
Query!
Country [138]
0
0
Poland
Query!
State/province [138]
0
0
Lublin
Query!
Country [139]
0
0
Poland
Query!
State/province [139]
0
0
Olsztyn
Query!
Country [140]
0
0
Poland
Query!
State/province [140]
0
0
Poznan
Query!
Country [141]
0
0
Poland
Query!
State/province [141]
0
0
Rzeszów
Query!
Country [142]
0
0
Poland
Query!
State/province [142]
0
0
Tomaszów Mazowiecki
Query!
Country [143]
0
0
Poland
Query!
State/province [143]
0
0
Warszawa
Query!
Country [144]
0
0
Poland
Query!
State/province [144]
0
0
Lódz
Query!
Country [145]
0
0
Portugal
Query!
State/province [145]
0
0
Guimarães
Query!
Country [146]
0
0
Portugal
Query!
State/province [146]
0
0
Lisboa
Query!
Country [147]
0
0
Portugal
Query!
State/province [147]
0
0
Loures
Query!
Country [148]
0
0
Portugal
Query!
State/province [148]
0
0
Porto
Query!
Country [149]
0
0
Portugal
Query!
State/province [149]
0
0
Vila Nova de Gaia
Query!
Country [150]
0
0
Russian Federation
Query!
State/province [150]
0
0
Moscow
Query!
Country [151]
0
0
Russian Federation
Query!
State/province [151]
0
0
Nizhny Novgorod
Query!
Country [152]
0
0
Russian Federation
Query!
State/province [152]
0
0
Podolsk
Query!
Country [153]
0
0
Russian Federation
Query!
State/province [153]
0
0
Saint Petersburg
Query!
Country [154]
0
0
Russian Federation
Query!
State/province [154]
0
0
Sankt-Peterburg
Query!
Country [155]
0
0
Russian Federation
Query!
State/province [155]
0
0
St. Petersburg
Query!
Country [156]
0
0
Slovakia
Query!
State/province [156]
0
0
Banská Bystrica
Query!
Country [157]
0
0
Slovakia
Query!
State/province [157]
0
0
Bratislava
Query!
Country [158]
0
0
Slovakia
Query!
State/province [158]
0
0
Kosice
Query!
Country [159]
0
0
Slovakia
Query!
State/province [159]
0
0
Michalovce
Query!
Country [160]
0
0
Slovakia
Query!
State/province [160]
0
0
Partizanske
Query!
Country [161]
0
0
Spain
Query!
State/province [161]
0
0
Badalona
Query!
Country [162]
0
0
Spain
Query!
State/province [162]
0
0
Barcelona
Query!
Country [163]
0
0
Spain
Query!
State/province [163]
0
0
L'Hospitalet de Llobregat
Query!
Country [164]
0
0
Spain
Query!
State/province [164]
0
0
La Coruna
Query!
Country [165]
0
0
Spain
Query!
State/province [165]
0
0
Madrid
Query!
Country [166]
0
0
Spain
Query!
State/province [166]
0
0
Murcia
Query!
Country [167]
0
0
Spain
Query!
State/province [167]
0
0
Málaga
Query!
Country [168]
0
0
Spain
Query!
State/province [168]
0
0
Sant Joan Despi
Query!
Country [169]
0
0
Spain
Query!
State/province [169]
0
0
Sevilla
Query!
Country [170]
0
0
Spain
Query!
State/province [170]
0
0
Valencia
Query!
Country [171]
0
0
Switzerland
Query!
State/province [171]
0
0
Bern
Query!
Country [172]
0
0
Switzerland
Query!
State/province [172]
0
0
Chur
Query!
Country [173]
0
0
Switzerland
Query!
State/province [173]
0
0
Winterthur
Query!
Country [174]
0
0
Taiwan
Query!
State/province [174]
0
0
Kaohsiung city
Query!
Country [175]
0
0
Taiwan
Query!
State/province [175]
0
0
Taichung
Query!
Country [176]
0
0
Taiwan
Query!
State/province [176]
0
0
Tainan
Query!
Country [177]
0
0
Taiwan
Query!
State/province [177]
0
0
Taipei 112
Query!
Country [178]
0
0
Taiwan
Query!
State/province [178]
0
0
Taipei City
Query!
Country [179]
0
0
Taiwan
Query!
State/province [179]
0
0
Taipei
Query!
Country [180]
0
0
Taiwan
Query!
State/province [180]
0
0
Taoyuan
Query!
Country [181]
0
0
Turkey
Query!
State/province [181]
0
0
Adana
Query!
Country [182]
0
0
Turkey
Query!
State/province [182]
0
0
Ankara
Query!
Country [183]
0
0
Turkey
Query!
State/province [183]
0
0
Istanbul
Query!
Country [184]
0
0
Turkey
Query!
State/province [184]
0
0
Izmir
Query!
Country [185]
0
0
Turkey
Query!
State/province [185]
0
0
Kadikoy/Istanbul
Query!
Country [186]
0
0
Turkey
Query!
State/province [186]
0
0
Karsiyaka
Query!
Country [187]
0
0
Turkey
Query!
State/province [187]
0
0
Kayseri
Query!
Country [188]
0
0
United Kingdom
Query!
State/province [188]
0
0
Blackpool
Query!
Country [189]
0
0
United Kingdom
Query!
State/province [189]
0
0
Cambridge
Query!
Country [190]
0
0
United Kingdom
Query!
State/province [190]
0
0
Guildford
Query!
Country [191]
0
0
United Kingdom
Query!
State/province [191]
0
0
Liverpool
Query!
Country [192]
0
0
United Kingdom
Query!
State/province [192]
0
0
London
Query!
Country [193]
0
0
United Kingdom
Query!
State/province [193]
0
0
Manchester
Query!
Country [194]
0
0
United Kingdom
Query!
State/province [194]
0
0
Newport
Query!
Country [195]
0
0
United Kingdom
Query!
State/province [195]
0
0
Nottingham
Query!
Country [196]
0
0
United Kingdom
Query!
State/province [196]
0
0
Portsmouth
Query!
Country [197]
0
0
United Kingdom
Query!
State/province [197]
0
0
Reading
Query!
Country [198]
0
0
United Kingdom
Query!
State/province [198]
0
0
Sheffield
Query!
Country [199]
0
0
United Kingdom
Query!
State/province [199]
0
0
Sutton
Query!
Country [200]
0
0
United Kingdom
Query!
State/province [200]
0
0
Taunton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04964934
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
AstraZeneca Clinical Study Information Center
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-877-240-9479
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP)
Query!
When will data be available (start and end dates)?
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Query!
Available to whom?
When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://astrazenecagroup-dt.pharmacm.com/DT/Home
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT04964934